{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5200","value":"9010"}]}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3030","value":"6330"}]}],"title":"Day 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Pharmacokinetic (PK) parameters were determined from the concentration-time profile using standard non-compartmental approaches and considering the profile over the complete sampling interval.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Sotorasib 960 mg PO QD until there was evidence of disease progression, intolerance to study medication, or withdrawal of consent.","id":"OG000","title":"Sotorasib"}],"paramType":"MEAN","populationDescription":"PK analysis set: all participants who received at least 1 dose of sotorasib and had at least 1 PK sample collected.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 0.25, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Days 1 and 8","title":"Maximum Observed Plasma Concentration (Cmax) of Sotorasib","type":"PRIMARY","unitOfMeasure":"ng/mL"}